Sumgen Completes $32 Million Round for Immunotherapy Antibodies
October 01, 2020 at 05:26 AM EDT
Sumgen Biotech of Hangzhou completed a $32 million Series B funding round to advance its portfolio of novel immunotherapy antibodies. The round was led by Addor Capital and co-led by Cowin Capital and Sinowisdom Investment. The proceeds will be used to fund clinical trials of the company's pipeline of ten oncology mAbs and construction of an antibody production facility in Hangzhou . Also participating in the round were BOCOM International, Shanghai Haoshuo Investment and Dynamic Capital. More details.... Share this with colleagues: // //
